Ravulizumab for paroxysmal nocturnal haemoglobinuria: a Single Technology Assessment
Previous
Previous
A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure
Next
Next